Menu +

Corcept Therapeutics To Announce First Quarter Financial Results and Corporate Update and Host Conference Call

Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on May 7, 2015. The Company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).

Conference Call Information

To participate, dial 1-888-771-4371 from the United States or 1-847-585-4405 internationally approximately 10 minutes before the start of the call. The passcode is 39586872.

A replay will be available through May 21, 2015 at 1-888-843-7419 from the United States and 1-630-652-3042 internationally. The passcode is 39586872.

About Corcept Therapeutics Incorporated

Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, oncologic and psychiatric disorders. Korlym®, a first generation competitive glucocorticoid receptor (GR) antagonist, is the company’s first FDA-approved medication. The company has a Phase 1/2 trial of mifepristone for the treatment of GR-positive triple-negative breast cancer, a Phase 1 trial of CORT125134, one of its proprietary, selective GR antagonists, and a portfolio of other selective GR antagonists that competitively block the effects of cortisol but not progesterone. It owns extensive intellectual property covering the use of GR antagonists, including mifepristone, in the treatment of a wide variety of metabolic, oncologic and psychiatric disorders. It also holds composition of matter patents for its selective GR antagonists.

CONTACT:

Investor Contact
Charles Robb
Chief Financial Officer
Corcept Therapeutics
650-688-8783
crobb@corcept.com

built@zoomedia
You are now leaving this website. If you would like to continue, click Continue.
Cancel Continue